← Leaderboards
Jennifer A Quinn
Duke University
$1,251,491
Attributed
$1,251,491
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,251,491 · 2
By mechanism
K23$626,265 · 1
R21$625,226 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- Darell D Bigner$25,397,506
- Henry S. Friedman$12,588,060
- Duane A. Mitchell$34,257,734
- David M. Ashley$7,073,119
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectClinical ResearchDrug ResistanceTemozolomideGliomaAntineoplasticsCarmustineDrug InteractionsEnzyme ActivityEnzyme InhibitorsMethylguanine Dna MethyltransferaseNeoplasm /Cancer ChemotherapyNitrosoureaPharmacokineticsProtein MetabolismImmunocytochemistryMagnetic Resonance ImagingClinical Trial Phase IiOutcomes ResearchDrug Screening /EvaluationNeoplasm /Cancer Relapse /RecurrenceNeoplastic ProcessGlioblastoma Multiforme
Grant awards (7)
Therapy of Temodar plus O6-Benzylguanine in Malignant G*$312,613
R21 · FY2004 · CA
AGT DEPLETION FOR THERAPY OF CNS TUMORS$125,253
K23 · FY2004 · NS
Temodar + O6-Benzylguanine Therapy in Malignant Glioma$312,613
R21 · FY2003 · CA
AGT DEPLETION FOR THERAPY OF CNS TUMORS$125,253
K23 · FY2003 · NS
AGT DEPLETION FOR THERAPY OF CNS TUMORS$125,253
K23 · FY2002 · NS
AGT DEPLETION FOR THERAPY OF CNS TUMORS$125,253
K23 · FY2001 · NS
AGT DEPLETION FOR THERAPY OF CNS TUMORS$125,253
K23 · FY2000 · NS